Request Free Sample ×
India Dry Age Related Macular Degeneration (AMD) Market Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

India Dry Age Related Macular Degeneration (AMD) Market

ID: MRFR/LS/46829-HCR
200 Pages
Vikita Thakur
Last Updated: April 06, 2026

India Dry Age-Related Macular Degeneration (AMD) Market Research Report By Stage (early age-related macular degeneration, intermediate age-related macular degeneration, late age-related macular degeneration), By Age Group (above 75 years, above 60 years, above 40 years), By Diagnosis and Treatment (treatment, diagnosis), By Route of Administration (oral, injectables) and By End Users (hospitals & clinics, diagnostic centers, academic & research institutes) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

India Dry Age Related Macular Degeneration (AMD) Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Chemicals and Materials, BY Stages (USD Million)
  49.     4.1.1 Early Age-Related Macular Degeneration
  50.     4.1.2 Intermediate Age-Related Macular Degeneration
  51.     4.1.3 Late Age-Related Macular Degeneration
  52.   4.2 Chemicals and Materials, BY Age Group (USD Million)
  53.     4.2.1 Above 75 Years
  54.     4.2.2 Above 60 Years
  55.     4.2.3 Above 40 Years
  56.   4.3 Chemicals and Materials, BY Route of Administration (USD Million)
  57.     4.3.1 Oral
  58.     4.3.2 Injectables
  59.   4.4 Chemicals and Materials, BY End Users (USD Million)
  60.     4.4.1 Hospitals & Clinics
  61.     4.4.2 Diagnostic Centers
  62.     4.4.3 Academic & Research Institutes
  63. 5 SECTION V: COMPETITIVE ANALYSIS
  64.   5.1 Competitive Landscape
  65.     5.1.1 Overview
  66.     5.1.2 Competitive Analysis
  67.     5.1.3 Market share Analysis
  68.     5.1.4 Major Growth Strategy in the Chemicals and Materials
  69.     5.1.5 Competitive Benchmarking
  70.     5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  71.     5.1.7 Key developments and growth strategies
  72.       5.1.7.1 New Product Launch/Service Deployment
  73.       5.1.7.2 Merger & Acquisitions
  74.       5.1.7.3 Joint Ventures
  75.     5.1.8 Major Players Financial Matrix
  76.       5.1.8.1 Sales and Operating Income
  77.       5.1.8.2 Major Players R&D Expenditure. 2023
  78.   5.2 Company Profiles
  79.     5.2.1 Regeneron Pharmaceuticals (US)
  80.       5.2.1.1 Financial Overview
  81.       5.2.1.2 Products Offered
  82.       5.2.1.3 Key Developments
  83.       5.2.1.4 SWOT Analysis
  84.       5.2.1.5 Key Strategies
  85.     5.2.2 Novartis (CH)
  86.       5.2.2.1 Financial Overview
  87.       5.2.2.2 Products Offered
  88.       5.2.2.3 Key Developments
  89.       5.2.2.4 SWOT Analysis
  90.       5.2.2.5 Key Strategies
  91.     5.2.3 Roche (CH)
  92.       5.2.3.1 Financial Overview
  93.       5.2.3.2 Products Offered
  94.       5.2.3.3 Key Developments
  95.       5.2.3.4 SWOT Analysis
  96.       5.2.3.5 Key Strategies
  97.     5.2.4 Bayer (DE)
  98.       5.2.4.1 Financial Overview
  99.       5.2.4.2 Products Offered
  100.       5.2.4.3 Key Developments
  101.       5.2.4.4 SWOT Analysis
  102.       5.2.4.5 Key Strategies
  103.     5.2.5 Pfizer (US)
  104.       5.2.5.1 Financial Overview
  105.       5.2.5.2 Products Offered
  106.       5.2.5.3 Key Developments
  107.       5.2.5.4 SWOT Analysis
  108.       5.2.5.5 Key Strategies
  109.     5.2.6 Alcon (CH)
  110.       5.2.6.1 Financial Overview
  111.       5.2.6.2 Products Offered
  112.       5.2.6.3 Key Developments
  113.       5.2.6.4 SWOT Analysis
  114.       5.2.6.5 Key Strategies
  115.     5.2.7 Horizon Therapeutics (IE)
  116.       5.2.7.1 Financial Overview
  117.       5.2.7.2 Products Offered
  118.       5.2.7.3 Key Developments
  119.       5.2.7.4 SWOT Analysis
  120.       5.2.7.5 Key Strategies
  121.     5.2.8 Apellis Pharmaceuticals (US)
  122.       5.2.8.1 Financial Overview
  123.       5.2.8.2 Products Offered
  124.       5.2.8.3 Key Developments
  125.       5.2.8.4 SWOT Analysis
  126.       5.2.8.5 Key Strategies
  127.     5.2.9 Santen Pharmaceutical (JP)
  128.       5.2.9.1 Financial Overview
  129.       5.2.9.2 Products Offered
  130.       5.2.9.3 Key Developments
  131.       5.2.9.4 SWOT Analysis
  132.       5.2.9.5 Key Strategies
  133.   5.3 Appendix
  134.     5.3.1 References
  135.     5.3.2 Related Reports
  136. 6 LIST OF FIGURES
  137.   6.1 MARKET SYNOPSIS
  138.   6.2 INDIA MARKET ANALYSIS BY STAGES
  139.   6.3 INDIA MARKET ANALYSIS BY AGE GROUP
  140.   6.4 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  141.   6.5 INDIA MARKET ANALYSIS BY END USERS
  142.   6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
  143.   6.7 RESEARCH PROCESS OF MRFR
  144.   6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
  145.   6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
  146.   6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
  147.   6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
  148.   6.12 CHEMICALS AND MATERIALS, BY STAGES, 2024 (% SHARE)
  149.   6.13 CHEMICALS AND MATERIALS, BY STAGES, 2024 TO 2035 (USD Million)
  150.   6.14 CHEMICALS AND MATERIALS, BY AGE GROUP, 2024 (% SHARE)
  151.   6.15 CHEMICALS AND MATERIALS, BY AGE GROUP, 2024 TO 2035 (USD Million)
  152.   6.16 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  153.   6.17 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
  154.   6.18 CHEMICALS AND MATERIALS, BY END USERS, 2024 (% SHARE)
  155.   6.19 CHEMICALS AND MATERIALS, BY END USERS, 2024 TO 2035 (USD Million)
  156.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  157. 7 LIST OF TABLES
  158.   7.1 LIST OF ASSUMPTIONS
  159.     7.1.1
  160.   7.2 India MARKET SIZE ESTIMATES; FORECAST
  161.     7.2.1 BY STAGES, 2025-2035 (USD Million)
  162.     7.2.2 BY AGE GROUP, 2025-2035 (USD Million)
  163.     7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  164.     7.2.4 BY END USERS, 2025-2035 (USD Million)
  165.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  166.     7.3.1
  167.   7.4 ACQUISITION/PARTNERSHIP
  168.     7.4.1

India Chemicals and Materials Market Segmentation

Chemicals and Materials By Stages (USD Million, 2025-2035)

  • Early Age-Related Macular Degeneration
  • Intermediate Age-Related Macular Degeneration
  • Late Age-Related Macular Degeneration

Chemicals and Materials By Age Group (USD Million, 2025-2035)

  • Above 75 Years
  • Above 60 Years
  • Above 40 Years

Chemicals and Materials By Route of Administration (USD Million, 2025-2035)

  • Oral
  • Injectables

Chemicals and Materials By End Users (USD Million, 2025-2035)

  • Hospitals & Clinics
  • Diagnostic Centers
  • Academic & Research Institutes

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓